/

Società

Im

Non verificato

Immune-Onc Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieOncologia

2 comunicati stampa

Guarda tutti i comunicati

27/02/2025

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Industria

Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche

Fonte

Immune-Onc Therapeutics, Inc.

Emittente

1.00

0

10/12/2024

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Eventi

Industria

Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

Fonte

Immune-Onc Therapeutics, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0